Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Iron metabolism disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Iron metabolism disorders. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2022-000894-16 Sponsor Protocol Number: NL79105.058.22 Start Date*: 2022-05-04
    Sponsor Name:Leiden University Medical Center
    Full Title: Predicting Response to Iron Supplementation in Patients with active Inflammatory Bowel Disease
    Medical condition: Inflammatory Bowel Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    20.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    20.1 10017947 - Gastrointestinal disorders 10021972 Inflammatory bowel disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000348-22 Sponsor Protocol Number: KER047-IR-201 Start Date*: 2021-08-10
    Sponsor Name:Keros Therapeutics, Inc.
    Full Title: A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA
    Medical condition: Iron-Refractory Iron-Deficiency Anemia (IRIDA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004667-13 Sponsor Protocol Number: N/A Start Date*: 2018-04-24
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King’s College Hospital NHS Foundation Trust
    Full Title: Effect of Iron (III) Isomaltoside 1000 on Cardiac Energetics in Anaemic and Non-anaemic Patients with Symptomatic Chronic Heart Failure and Iron Deficiency: The Ferric Iron in Heart Failure (FERRIC...
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    20.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000144-25 Sponsor Protocol Number: 234820 Start Date*: 2019-03-08
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Multicentre prospective double blinded randomised controlled trial of the effect of intravenous iron supplementation and exercise training in Iron deficient, but not anaemic, patients with Chronic ...
    Medical condition: Iron deficiency in stage 3-4 CKD
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 100000004851 10066763 Chronic iron deficiency anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-002981-11 Sponsor Protocol Number: ThromboCa Start Date*: 2013-09-24
    Sponsor Name:Medizinische Universität Wien, Klinik für Innere Medizin III, Abteilung für Gastroenterologie und Hepatologie
    Full Title: Iron Deficiency, Platelet Phenotype and Thromboembolism in Cancer Patients
    Medical condition: colorectal cancer, iron deficiency
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    16.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001695-19 Sponsor Protocol Number: FER-CARS-05 Start Date*: 2011-12-22
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose with Placebo in Patients with Chronic Heart Failure and Iron Deficiency
    Medical condition: Iron deficiency in patients with chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    14.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) SE (Completed) GB (Completed) IE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004370-26 Sponsor Protocol Number: R2451 Start Date*: 2020-02-14
    Sponsor Name:Hull University Teaching Hospitals NHS Trust
    Full Title: Exploratory single centre prospective 12-week comparative double blinded randomised trial of the impact of high-dose iron isomaltoside vs iron carboxymaltose on measures of FGF23, bone metabolism a...
    Medical condition: Iron deficiency anaemia associated with Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10005329 - Blood and lymphatic system disorders 10066763 Chronic iron deficiency anaemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    20.0 10005329 - Blood and lymphatic system disorders 10055738 Iron deficiency anaemia, unspecified LLT
    20.1 10022891 - Investigations 10072681 Fibroblast growth factor 23 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000603-40 Sponsor Protocol Number: FER-CARS-04 Start Date*: 2011-06-20
    Sponsor Name:Vifor (International) Inc.
    Full Title: Multicentre, prospective, randomised, 2-arm study to assess the impact of ferric carboxymaltose on exercise capacity in chronic heart failure patients with iron deficiency
    Medical condition: Iron deficiency in patients with chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10008908 Chronic heart failure LLT
    14.1 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017737-21 Sponsor Protocol Number: IDNA 2009-01 Start Date*: 2011-01-18
    Sponsor Name:Vifor Pharma
    Full Title: A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficie...
    Medical condition: Treatment of iron deficient non anaemic women with ferric carboxymaltose.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022970 Iron deficiency LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003819-56 Sponsor Protocol Number: 26193789 Start Date*: 2020-06-12
    Sponsor Name:Centre for Surgical Science
    Full Title: Effects of intravenous administered iron in non-anemic iron deficient patients with colorectal cancer. A double blinded clinical randomized trial.
    Medical condition: Iron-deficiency in colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    20.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002096-26 Sponsor Protocol Number: MV-3-2017 Start Date*: 2017-08-24
    Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest
    Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in dialysis patients.
    Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10027425 Metabolic bone disorders HLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10078095 Chronic kidney disease-mineral and bone disorder PT
    20.0 100000004869 10012347 Dependence on renal dialysis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003532-12 Sponsor Protocol Number: CICL670AUS04 Start Date*: 2016-03-07
    Sponsor Name:Novartis
    Full Title: An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10054658 Thalassemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004016-22 Sponsor Protocol Number: LA61-0218 Start Date*: 2018-12-27
    Sponsor Name:ApoPharma Inc.
    Full Title: Safety and acceptability of deferiprone delayed release tablets in patients with systemic iron overload
    Medical condition: Systemic iron overload
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10065973 Iron overload PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000574-30 Sponsor Protocol Number: VIT-RLS-2012-013 Start Date*: 2013-09-23
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Randomised, Assessor- and Patient-blind, Multicentre, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Outcomes in Iron ...
    Medical condition: Non-anaemic iron deficient patients with restless legs syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-015767-14 Sponsor Protocol Number: FER-FID-CHEMO Start Date*: Information not available in EudraCT
    Sponsor Name:Vifor (International) AG
    Full Title: A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with lymphoid malignancies...
    Medical condition: Anaemic subjects with lymphoid malignancies and functional iron deficiency receiving chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025631 Malignant lymphoid neoplasm NOS LLT
    14.0 10005329 - Blood and lymphatic system disorders 10002034 Anaemia PT
    14.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005830-12 Sponsor Protocol Number: RF-2010-2321799 Start Date*: 2012-10-30
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Parenteral iron supplementation, chemoreflex response, quality of life and exercise capacity in patients with chronic heart failure
    Medical condition: Chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001077-13 Sponsor Protocol Number: CICL670A2417 Start Date*: 2011-08-11
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio clínico multicéntrico, aleatorizado, comparativo, de distintos regímenes de administración de deferasirox en la tolerabilidad gastrointestinal (GI), en pacientes con síndrome mielodisplásic...
    Medical condition: Sobrecarga de hierro de riesgo bajo o intermedio (int-1) en pacientes con síndrome mielodisplásico (SMD) con ferritina > 1000 mcg/L en la selección o antecedentes de transfusión de por lo menos 20 ...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10022979 Iron excess HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001718-32 Sponsor Protocol Number: FBS0701CTP-07 Start Date*: 2011-09-07
    Sponsor Name:FERROKIN BIOSCIENCES INC.
    Full Title: A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of FBS0701 in a Pediatric Population with Transfusional Iron Over...
    Medical condition: Patients with documented transfusional iron overload ages 6 to less than 18 years old will be studied. Patients with transfusion-dependent anemias will be eligible regardless of the cause of thei...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10065974 Chronic iron overload LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000650-64 Sponsor Protocol Number: CICL670E2419 Start Date*: 2012-11-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS)
    Medical condition: iron overload in patients with non-transfusion dependent thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10022979 Iron excess HLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004608-37 Sponsor Protocol Number: FER-CARS-02 Start Date*: 2007-07-27
    Sponsor Name:Vifor Pharma, Vifor (International) Ltd.
    Full Title: A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) with placebo in patients with chronic heart failure and iro...
    Medical condition: iron deficiency in patients with chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) CZ (Completed) GR (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 14:58:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA